According to an informed source, USTR intimated that next week’s ACTA meeting in Washington DC will be attended by all the negotiating parties and that discussions would include all issues under consideration in ACTA. We are still awaiting a response from USTR regarding the attendees, scope and purpose of the meeting but this new information seems to be indicative of nothing short of the next ACTA round.
Earlier, US government officials had informed that the an intersessional meeting would be held the week of 16 August in Washington DC. Continue Reading →
From the FDA page on the Orphan Drug Tax Credit. Incentives TAX CREDIT (See Footnote 1 below) FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR CONDITIONS Introduction Section 45C of the Internal Revenue Code of 1954 allows a credit… Continue Reading →
TAX CREDIT
(See Footnote 1 below)
FOR TESTING EXPENSES FOR
DRUGS FOR RARE DISEASES OR CONDITIONS
Introduction
Section 45C of the Internal Revenue Code of 1954 allows a credit against tax, up to 50 percent of certain clinical testing expenses related to the use of a drug for a rare disease or condition after it is designated as an orphan drug.
December 7, 2010. Press release from Fabry patients: DHHS denies patient’s march-in request to end Genzyme’s rationing of treatment for Fabry Disease citing that FDA rules block manufactures from supplying the drug in a timely manner.
This week, the European Commission conducted two briefings for members of the European Parliament.
On Monday, July 12, members of the European Parliament’s INTA Committee (Committee on International Trade) were briefed by EU ACTA negotiators Luc Devigne and Pedro Valesco in a private, closed meeting.
Today, July 13, Karel De Gucht, EU Commissioner for Trade held a public briefing in the LIBE Committee (Committee on Civil Liberties, Justice and Home Affairs). The video is now available here
At a June 28, 2010 Geneva workshop on the Anti-Counterfeiting Trade Agreement. Dr. Zhao Hong, from the Permanent Mission of the People’s Republic of China to the World Trade Organization, distributed a proposal that was prepared for the June 8-9, 2010 meeting of the WTO TRIPS Council:
Decisions to be taken
Decision of the TRIPS Council on the Relationship between the TRIPS Agreement and Intellectual Property Provisions of bilateral, plurilteral Trade Agreeements
The EU position came out in a proposal for a Joint Recommendation with 9 articles in 11 pages. It is hard to believe but it is worst than the US proposal and it is even worst than nothing. It is an outrageous “roll back” recommendation. It does make clear who’s the boss in the commission. The publishers apparently. Their proposal is bold. Here’s a quick read:
There is a negotiation in the WIPO SCCR over the work program on copyright limitations and exceptions for persons with disabilities. Some countries favor a negotiation on a binding treaty. The US government is asking that the SCCR set aside work on the treaty, and focus instead on a non-binding recommendation to address a limited set of issues relating to the import and export of works created under an exception. The US government asserts that treaties would take a very long time to negotiate, ratify and implement. Continue Reading →